Updates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma - Episode 5

Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

August 24, 2022
Sunandana Chandra, MD, MS

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.